Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
37 hedge funds and large institutions have $61.9M invested in Constellation Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
6% more funds holding
Funds holding: 35 → 37 (+2)
15% less capital invested
Capital invested by funds: $73M → $61.9M (-$11.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$1.46M |
| 2 |
First Eagle Investment Management
New York
|
+$754K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$423K |
| 4 |
JRP
Jasper Ridge Partners
Menlo Park,
California
|
+$372K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$162K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.21M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$957K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$525K |
| 4 |
BlackRock
New York
|
-$502K |
| 5 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$351K |
CNST Hedge Fund Activity: Q4 2018 in Review
37 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q4 2018, worth a combined $61.9M — down 15% from $73M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CNST positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Casdin Capital, adding an estimated $1.46M. The largest seller was EcoR1 Capital, cutting an estimated $1.21M.
- 37 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q4 2018, up from 35 in Q3 2018.
- Funds reported $61.9M of Constellation Pharmaceuticals, Inc. stock for Q4 2018, down 15% quarter-over-quarter.
- 8 funds opened new Constellation Pharmaceuticals, Inc. positions in Q4 2018 and 6 closed out, a net change of +2 holders.
- The largest Constellation Pharmaceuticals, Inc. buyer in Q4 2018 was Casdin Capital, an estimated $1.46M added.
- The largest Constellation Pharmaceuticals, Inc. seller in Q4 2018 was EcoR1 Capital, an estimated $1.21M sold.
Based on aggregated 13F filings for Q4 2018.